IQWiG early assessment lukewarm on Servier's Lonsurf

24 November 2016

The German Institute for Quality and Efficiency in Health Care (IQWiG) has published a dossier on Lonsurf (trifluridine/tipiracil) as part of the cost-effectiveness watchdog's analysis of the benefits of the combination treatment in metastatic colorectal cancer.

The IQWiG is assessing the therapy, which is marketed by independent French drugmaker Servier, in adult patients whose disease has progressed despite treatment or who cannot be given other treatments.

Lonsurf was approved by the European Medicines Agency in April and it has already received a positive recommendation from the IQWiG equivalent for England and Wales, the National Institute for Health and Care Excellence (NICE), in this patient group.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK